Wealth Quarterback’s CRISPR Therapeutics CRSP Stock Holding History

Wealth Quarterback’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,909	Closed	-$359K	–	120
2023 Q3	$359K	Sell	7,909 -166	-2%	-$8.57K	0.31%	76
2023 Q2	$453K	Sell	8,075 -164	-2%	-$9.31K	0.31%	72
2023 Q1	$373K	Buy	8,239 +34	+0.4%	+$1.65K	0.32%	71
2022 Q4	$334K	Sell	8,205 -13	-0.2%	-$690	0.28%	78
2022 Q3	$537K	Sell	8,218 -217	-3%	-$15.7K	0.57%	45
2022 Q2	$513K	Buy	+8,435	New	+$496K	0.4%	53
2021 Q3	$638K	Sell	5,943 -205	-3%	-$25.7K	0.42%	53
2021 Q2	$996K	Buy	+6,148	New	+$748K	0.61%	33
2020 Q2	–	Sell	-75	Closed	-$3.18K	–	244
2020 Q1	$3.18K	Hold	75	–	–	﹤0.01%	685
2019 Q4	$4.57K	Buy	+75	New	+$4.09K	﹤0.01%	644

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wealth Quarterback's CRSP Position: Q4 2023 in Review

Wealth Quarterback sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 7,909 shares — an estimated $359K sold.

Wealth Quarterback first reported a position in CRSP in Q4 2019 and held it in 10 quarters. The position peaked at $996K in Q2 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Wealth Quarterback reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Wealth Quarterback sold 7,909 CRISPR Therapeutics shares in Q4 2023, an estimated $359K.
Wealth Quarterback first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 10 quarters.
Wealth Quarterback's CRISPR Therapeutics position peaked at $996K in Q2 2021.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Wealth Quarterback's 13F filing for Q4 2023, filed 13 Feb 2024.